Welcome to Penzbeg One of Euope s lagest biotech facilities
The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
Whee it all began The Penzbeg site in 1957
Whee it all began The Penzbeg site in 1957 and 2004
The Penzbeg site today Founded: 1972 (Boehinge Mannheim) Aea: 310,000 m² Employees: 3,459 (Dec. 03) Invested capital: 870 Mill. (Dec. 03)
The Penzbeg site Headcount Numbe of employees 4.000 3.500 3.000 2.500 2.000 1.500 1.000 500 0 3.277 3.459 3.073 2.719 2.866 2.464 1998 1999 2000 2001 2002 2003 *until 2000 incl. Tutzing
The Penzbeg site Employee qualifications Advanced taining 8% Technical college gaduates 9% Univesity gaduates 25% Vocational taining 53% unskilled 5%
The Penzbeg site Aveage age 38,5 38,4 38,5 38,4 38,4 1999 2000 2001 2002 2003 * incl. Tutzing until 2000
The Penzbeg site Capital expenditue
The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
Penzbeg s Role Penzbeg is the only location woldwide whee both divisions have on-site eseach, development and poduction facilities Diagnostics (appox. 2,600 employees) Phama (appox. 710 employees) R & D Reseach Poduction Poduction
Penzbeg s Role Biotechnology One of Euope s lagest Biotech facilities Lagest Biotech site in the Roche Goup Supplies poducts fo Diagnostics and Phamaceuticals Most Diagnostics poducts ae biotechnology based Poduces 4 impotant biophamaceuticals
The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
Roche Diagnostics Poduct potfolio Life Science Reseach in-vito diagnostics maket Reseach Pofessionals Consumes Applied Science Modula Analytics E 170 Molecula Diagnostics LightCycle Omni S Centalized Diagnostics Nea Patient Testing Accu-Chek Go Cobas Amplipep Diabetes Cae
Roche Diagnostics Regional headquates and R&D centes Bugdof Indianapolis Rotkeuz Basel Mannheim Penzbeg Gaz Applied Science Molecula Diagnostics Centalized Diagnostics leasanton/ Alameda Tokyo Nea Patient Testing Diabetes Cae Banchbug Regional headquates Bacelona Singapoe Copoate headquate
Penzbeg s Role Diagnostics R&D cente fo eagents in - clinical chemisty - immunology Cente of Excellence fo active ingedients (R&D and Poduction)
Biotechnology in Penzbeg Diagnostics Diagnostic eagents and systems Reseach eagents (e.g. estiction enzymes) Industial poducts (e.g. catalase) Enzyme tests (e.g. cholesteol) Immune tests (e.g. tumo makes) Nucleic acid diagnosis (e.g. HIV) Diabetes: Blood suga measuement Enzymes e.g. glucose oxidase
The Roche Goup s lagest biotech facility The Penzbeg site Pofile Role Diagnostics Phamaceuticals Futue
Penzbeg s Role Phamaceuticals Diagnostics (appox. 2,600 employees) Phama (appox. 710 employees) R & D Reseach Poduction Poduction
The Roche Goup A global leade in biophamaceuticals Roche Goup 1st half 2004 MabThea/Rituxan NeoRecomon/Epogin Pegasys/Copegus Cellcept Heceptin Rocephin Xenical Xeloda Nutopin/Potopin Kytil geen: Biophamaceuticals Sales in CHF m 1624 1020 783 719 674 684 311 243 225 220 Change H1/2004 vs. H1/2003 + 31% + 3% + 142% + 19% + 26% + 0% + 0% - 11% + 10% + 13%
Penzbeg s Role Phamaceuticals One of 4 Roche s phamaceutical eseach centes Lagest eseach location fo oncology Cente of Excellence fo phamaceutical active ingedients
Phama Biologicals Penzbeg Biologicals Tech.Dev. and Manufactuing Biologicals Technical Development Biologicals R&D New Biologicals Manufactuing Biologicals Manufactuing
Roche global R&D centes Pleasanton Indianapolis Nutley Palo Alto Genentech Mannheim Penzbeg Penzbeg Basel Rotkeuz Basel RCMG Gaz Phama Biotechnology R&D Centes Chugai Phama Centes Diagnostics Centes Roche Goup
Biotechnology poduction in Penzbeg Phamaceuticals Active ingedients fo dugs: - Eythopoietin / Neoecomon - Recombinant plasminogen activato Rapilysin / eteplase - Tastuzumab / Heceptin - Peg-Intefeone-alpha 2a/ Pegasys - Ove 200 antibodies fo diagnostic tests - Active ingedients fo clinical studies Phama biotech poduction Appoved by FDA and EMEA
The Roche Goup s lagest biotech facility Site Penzbeg Pofile Role Diagnostics Phamaceuticals Futue
The Penzbeg site Biotechnology pojects Building 354 EPO (Eythopoietin) Investment: 182 m Completion: July 2005
The Penzbeg site Biotechnology pojects Building 345 Monoclonal antibodies fo Diagnostics Investment: 31.4 m Completion: Mach 2006
The Penzbeg site Biotechnology pojects Building 361/362 Bio Heceptin Investment: 290 m Completion: Decembe 07